Amylyx Pharma Q1 2024 GAAP EPS $(1.75)May Not Be Comparable To $0.01 Estimate, Sales $88.643M Miss $98.346M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amylyx Pharmaceuticals reported a Q1 2024 GAAP EPS of $(1.75), which is not comparable to the estimated $0.01. Their sales for the quarter were $88.643 million, missing the estimated $98.346 million.
May 09, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Amylyx Pharmaceuticals reported a significant miss in both GAAP EPS and sales for Q1 2024, with EPS at $(1.75) against an estimate of $0.01 and sales of $88.643M versus an expected $98.346M.
The reported earnings significantly missed analyst expectations, both in terms of EPS and sales revenue. Such misses typically lead to negative investor sentiment in the short term, potentially causing a decrease in stock price as market participants adjust their expectations for the company's financial health and future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100